pharmaphorum Daily Newsletter - 4th Dec.
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
As mid-week arrives, Wednesday’s news reveals that Genmab has expanded its pipeline with a $630m deal with UK biotech Scancell .
Meanwhile, #Zepbound has topped #Wegovy in first head-to-head weight-loss trial and the UKHSA has ordered 5 million H5N1 bird flu vaccines from CSL in a pandemic preparedness step.
Elsewhere, an The Association of the British Pharmaceutical Industry (ABPI) report has stated that the #MHRA isn't sufficiently funded to meet its obligations, which could threaten UK investment in life sciences, and Applied Therapeutics, Inc. has received a warning letter from the FDA over a trial of its rare disease drug govorestat, which was rejected by the agency last week.
In our longer reads today, learn more about patient centricity in the drug development process, with a sponsored feature from ICON plc , which looks at the importance of outcome measures, rather than endpoints. In other in-depth articles today, discover how flow cytometry is revolutionising cancer diagnosis and treatment, why BCIs could redefine precision medicine, and the reasons for innovation in multiple myeloma yet lagging behind other cancer types.
News
Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.
Eli Lilly is playing catch-up to Novo Nordisk in the fast-growing obesity therapy sector but has new data that could tip the balance in its favour.
The UKHSA has taken steps to prepare for a possible bird flu outbreak by placing an order with Seqirus for millions of H5 vaccine doses.
The MHRA isn't sufficiently funded to meet its obligations and that could threaten UK investment in life sciences, according to an ABPI report.
Applied Therapeutics gets a warning letter from the FDA over a trial of rare disease drug govorestat, which was rejected by the agency last week.
Views & Analysis
Pharmaceutical companies face increasing pressure to demonstrate not only the efficacy of their treatments, but also the impact of these treatments on patients' lives. This interest in and the evolving regulatory requirement to put patients at the centre of the drug development process – patient-centric from end to end – means pharmaceutical sponsors must design clinical trials with patient-centred outcomes in mind - pharmaphorum spoke with Sonia Bothorel, Managing Director of Mapi Research Trust and Outcome Measures Solutions, a leader in the distribution and facilitation of clinical outcome assessments.
As the incidence of cancer rises around the world, the demand for faster, more precise diagnoses is also on the rise. This demand will only intensify over time, as the worldwide incidence of cancer is expected to rise 55% between 2022 and 2045.
BCIs could emerge as a ground-breaking tool for the pharma industry, offering new ways to understand and treat complex conditions.
领英推荐
Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies.
Jackie Marchington is Head of Compliance and Ethics for IPG Health Medical Communications. Marchington has been working in the medical communications space for more years than is polite to ask. She worked up through the medical writing/editing side of the business, dabbled in IT for a bit, then moved into increasingly operational roles in agency leadership, before stepping out of the delivery side of the business in 2022 to take up her current role.
Podcasts & Videos
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Sharmeen Roy, chief scientist at DoseMe, for a conversation on precision medicine tools and how pharmacokinetic (or PK) and pharmacodynamic (or PD) characteristics are a – long overdue – trend in pharma at the moment, from lead identification right up to final-stage clinical trials.
In this pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics, a company working in the in vivo cell therapy space.
Clinical research is full of challenges, from recruitment to data management to global resourcing. Working with a functional service provider (FSP) can be a great option for meeting these needs. But what exactly is an FSP, and what are the advantages to working with one? In this interview, brought to you by Advanced Clinical, Programme Directors Lori Fletcher and Amber Beimer speak with pharmaphorum editor-in-chief Jonah Comstock and clear up some misconceptions that FSPs are merely staffing agencies.
In today’s podcast, web editor Nicole Raleigh is joined by Jesse Mendelsohn, senior vice president of Model N’s Center of Excellence, for a conversation that explores multiple aspects of the drug pricing debate in America – speaking before President-Elect Donald Trump confirmed his nomination of Robert F Kennedy Jr as US Health and Human Services Secretary.
In a new podcast, web editor Nicole Raleigh speaks with Dr Samuel Ewing, global head of pharma partnerships at Doccla, about the next generation of digital tools such as wearable medical devices, as well as remote patient monitoring and digital healthcare generally.
Webinars & White Papers
An exclusive webinar, sponsored by Trueblue, explores how life sciences organisations are leveraging the power of AI-driven strategic insights to revolutionise decision-making, enhance customer engagement, and gain a competitive edge. Available now on demand.
In this webinar, sponsored by PurpleLab, learn how to gain a competitive edge by understanding physician prescribing behaviour in target markets. Available now on demand.
In a webinar sponsored by Syneos Health - with Atlas Clinical Research’s Chief Executive Officer Mark Scullion, and Batisha Anson, Global Head of Patient Diversity and Health Equity at Syneos Health - learn more about the site experience for clinical research sites. Now available on demand.
Global reach, personal touch: Mastering customer engagement at scale Discover how to balance personalised engagement with regulatory compliance across global pharma markets in a webinar presented by EVERSANA INTOUCH. Available on demand now.
Beyond clinical: Boosting recruitment and retention with SDOH data In a Socially Determined sponsored webinar, discover how industry leaders are harnessing non-clinical data to enhance recruitment, retention, and broader evidence generation. Now available on demand.